Other · Gene silencing: proprotein convertase subtilisin/kexin type 9 (PCSK9) · developed by Novartis
Inclisiran is a double-stranded small interfering RNA conjugated to GalNAc to target hepatocytes, where it directs the breakdown of PCSK9 mRNA. This reduces PCSK9 protein production, increasing LDL-C receptor recycling and LDL-C clearance from the circulation. It is studied in atherosclerotic cardiovascular disease, primary prevention and cardiometabolic syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 19, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06909565 | Phase 4 | Percutaneous Coronary Intervention | Recruiting | NVS |
| NCT07102628 | Phase 3 | Acute Coronary Syndrome | Active not recruiting | NVS |
| NCT05030428 | Phase 3 | Atherosclerotic Cardiovascular Disease | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atherosclerotic Cardiovascular DiseaseCardiometabolic SyndromeDrug InteractionsLDL-Cholersterol LoweringPolypharmacyPrimary Prevention
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →